Archives of Toxicology

, Volume 65, Issue 7, pp 525–531

Arsenic: opportunity for risk assessment

  • Gerhard Stöhrer
Review Article

Abstract

Arsenic is a human carcinogen that in small amounts is widely distributed in food and water. It has been regulated for almost 100 years worldwide and in the United States, on the judgment of the Royal Commission on Arsenic that a classical threshold of toxicity exists and that a daily intake of 400 (Μg/day is safe. Modern regulatory thinking in the United States has not accepted safe levels for carcinogens and is thus in conflict with the arsenic standard. Recent epidemics of arsenicism have quantitatively confirmed that threshold not only for the non-cancerous arsenical skin lesions but also for arsenical skin and internal cancers. Research shows that arsenic is a general gene inducer. Genes induced are involved in proliferation, recombination, amplification and the activation of viruses. This characterizes arsenic as anindirect carcinogen and provides a molecular basis for risk assessment and the observed threshold dose response. In the United States at present, about 300 cases of occupational arsenical cancer, declining in numbers, are known. Background arsenic below the drinking water standard is not known to have produced disease. The conspicuous nature of arsenical skin disease presents an unusual opportunity for a simplified survey of arsenical skin disease to support regulatory standards for arsenic.

Key words

Arsenic Risk assessment Gene induction Skin disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albert RE, Train RE, Anderson E (1977) Rationale developed by the Environmental Protection Agency for the assessment of carcinogenic risks. J Natl Cancer Inst 58: 1537–1541PubMedGoogle Scholar
  2. Andelman JB, Barnett M (1986) Feasibility study to resolve questions on the relationship of arsenic in drinking water to skin cancer. In: Kopfler FC, Craun GF (eds) Environmental epidemiology. Lewis Publishers, Inc. 1986 Chelsea, MichiganGoogle Scholar
  3. Amtmann E, Sauer G (1982) Activation of non-expressed bovine papilloma virus genomes by tumor promoters. Nautre 296: 675–677CrossRefGoogle Scholar
  4. Appel KE, Hildebrandt AG (1984) Tumorpromotors, Documentation of an Expert Discussion; MMV Medizin Verlag München. 177 pages in German. The conclusions of this workshop have been published: Appel KE, Bannasch P, Fürstenberger G, Hapke HJ, Hecker E, Hildebrandt AG, Koransky W, Marks F, Neumann HG, Ohnesorge FK, Preussmann R and Schulte-Herrmann (1990) Chemical carcinogenesis: definitions of terms used. J. Cancer Res Clin Oncol 116: 232–236Google Scholar
  5. Beckman G, Beckman L, Nordenson I (1977) Chromosome aberrations in workers exposed to arsenic. Environ Health Perspect 19: 1145–146Google Scholar
  6. Bolt HM, Gelbke HP, Greim H, Kimmerle G, Laib, HG, Neumann HK, Norpoth HK, Pott F, Steinhoff D, Wardenbach P (1988) Materials suspected of carcinogenic potential: problems and possibilities for solutions. Arbeitsmed Sozialmed PrÄventivmed 23: 139–144 (in German)Google Scholar
  7. Borgono JM, Greiber R (1972) Epidemiological study of arsenicism in the city of Antofagasta. In Hemphill DD (ed) Trace substances in environmental health V. University of Missouri Press, Columbia, MO, USAGoogle Scholar
  8. Burgdorf W, Kurvink K, Cervenka J (1977) Elevated sister chromatid exchange rate in lymphocytes of subjects treated with arsenic. Hum Genet 36: 69–72CrossRefPubMedGoogle Scholar
  9. Chen C-J, Juo T-L, Wu M-M (1988) Arsenic and cancers. The Lancet, Feb 20, 414–415Google Scholar
  10. Crump KS, Hoel DG, Langley CH, Peto R (1976) Fundamental processes and their implications for low dose risk assessment. Cancer Res 36: 2973–2979PubMedGoogle Scholar
  11. Deutsche Forschungsgemeinschaft (1988) Risk assessment for tetrachloroethylene. In: Maximum concentrations at the workplace and biological tolerance values for working materials. Verlag Chemie, WeinheimGoogle Scholar
  12. Enterline PE, Marsh GM (1980) Mortality studies of smelter workers. Am J Ind Med 1: 251–259PubMedGoogle Scholar
  13. Fahrig R (1984) Genetic mode of action of cocarcinogens and tumor promoters in yeast and mice. Mol Gen Genet 194: 7–14CrossRefPubMedGoogle Scholar
  14. Feron VJ, Grice HC, Griesemer R, Peto R, Agathe C, Althoff G, Ito N, Kimmerle G, Kroes R, Mohr U, Napalkov NP, Odashima S, Page NP, Schramm T, Steinhoff D, Sugar J, Tomatis I, Uehleke H, Vouk V (1980) Basic requirements for long term assays for carcinogenicity. In: Long term and short term screening assays for carcinogens. IARC Monographs, Supplement 2. International Agency for Research on Cancer, Lyon, France, pp 21–83Google Scholar
  15. Gartrell MJ, Craun JC, Podrebarac DS, Gunderson EL (1986) Pesticides, selected elements and other chemicals in adult total diet samples. J Assoc Off Anal Chem 69: 146–161PubMedGoogle Scholar
  16. Graham JH, Helwig EB (1972) Premalignant cutaneous and mucocutaneous diseases. In: Graham JH, Johnson A, Helwig EB (eds) Dermal Pathology, Harper and Row, PhiladelphiaGoogle Scholar
  17. Great Britain (1903) Royal Commission on Arsenic Poisoning, Part 2 Report. Wyman and Sons, London. A summary is published as: The final report of the Royal Commission on Arsenic Poisoning. Lancet, Dec 1903, pp 1674–1676 and 1746–1748Google Scholar
  18. Guha Mazumder DN, Chakraborty AK, Ghose A, Gupta JD, Chakraborty DP, Dey SB, Chattopadhyay (1988) Chronic arsenic toxicity from drinking tube well water in rural West Bengal. Bull WHO 66: 499–506PubMedGoogle Scholar
  19. Hecker E, Rippmann F (1988) Quantitative determination of experimental threshold dose (no-effect-levels) for environmental promoters in the initiation-promotion protocol on skin of NMRI mice. Naunyn-Schmiedeberg's Arch Pharmacol (Suppl.) 338: R 11Google Scholar
  20. Hill RN, Erdreich LS, Paynter OE, Roberts PA, Rosenthal SA, Wilkinson CF (1989) Thyroid follicular cell carcinogenesis. Fundam Appl Toxicol 12: 629–697CrossRefPubMedGoogle Scholar
  21. Huh N-h, Satoh MS, Shiga J, Rajewski MF, Kuroki T (1989) Immunological detection of O4-ethylthymine in liver DNA of individuals with and without malignant tumors. Cancer Res 49: 93–97PubMedGoogle Scholar
  22. Hutchinson J (1888) On some examples of arsenic keratoses of the skin and of arsenic cancer. Trans Pathol Soc (London) 39: 352–363Google Scholar
  23. Interagency Regulatory Liaison Group (IRLG) (1979) Scientific basis for identification of potential carcinogens and estimation of risks. J Natl Cancer Inst 63: 245–267Google Scholar
  24. Kroes R (1987) Contribution of toxicology towards risk assessment of carcinogens. Arch Toxicol 60: 224–228CrossRefPubMedGoogle Scholar
  25. Lee TC, Ostamura M, Barrett JC (1985) Carcinogenesis 6: 1421–1425PubMedGoogle Scholar
  26. Lee T-C, Tanaka N, Lamb PW, Gilmer TM, Barrett CJ (1988) Induction of gene amplification by arsenic. Science 241: 79–81PubMedGoogle Scholar
  27. Madhukar BV, Brewster DW, Matsumura F (1984) Effects of in vivo administered TCDD on receptor binding of epidermal growth factor. Proc Natl Acad Sci USA 81: 7407–7411PubMedGoogle Scholar
  28. McDonnell JM, Mayr AJ, Martin WJ (1989) DNA of human papilloma virus type 16 in dysplastic and malignant lesions of the conjunctiva and cornea. N Engl J Med 320: 1442–1445PubMedGoogle Scholar
  29. Miller EC (1978) Some current perspective on chemical carcinogenesis in humans and experimental animals. Cancer Res 38: 1479–1496PubMedGoogle Scholar
  30. Mitchell N, Stöhrer G (1986) Mutagenesis originating in site-specific DNA damage. J Mol Biol 191: 177–180CrossRefPubMedGoogle Scholar
  31. Mitchell PJ, Tjian R (1989) Transcriptional regulation in mammalian cells by sequence specific DNA Binding proteins. Science 245: 371–378PubMedGoogle Scholar
  32. Morton W, Starr G, Pohl D, Stoner RS, Wagner S, Weswig P (1976) Skin cancer and water arsenic in Lane County, Oregon. Cancer 37: 2523–2532Google Scholar
  33. Neubauer O (1947) Arsenical cancer: a review. Br J Cancer 1: 192–251Google Scholar
  34. Office of Science and Technology Policy (1985) Chemical carcinogens: review of the science and its associated principles. Federal Register 50: 10372–10442Google Scholar
  35. Parker KR, von Borstel RC (1987) Base substitution and frameshift mutagenesis by sodium chloride and potassium chloride in Saccharomyces cerevisiae. Mutat Res 189: 11–14CrossRefPubMedGoogle Scholar
  36. Ptashne M (1989) How gene activators work. Sci Am 260 [1]: 40–47PubMedGoogle Scholar
  37. Redfield RR, Burke DS (1988) HIV infection: the clinical picture. Sci Am 259 [4]: 90–100Google Scholar
  38. Rice JD, Nikdel S, Purvis AC (1985) Maturity spray residue determination and early season acid accumulation in grapefruit. Proc Fla State Hortic Soc 98: 224–228Google Scholar
  39. Ries LA, Hankey BF, Edwards BK (1990) Survey epidemiology and end result. Cancer Statistics Review 1973–87. NIH Publ. 90–2789Google Scholar
  40. Schönthal A, Herrlich P, Rahmsdorf HJ, Ponta H (1988) Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol. Cell 54: 325–334CrossRefPubMedGoogle Scholar
  41. Schottenfeld D, Gantt RC, Wynder EL (1974) Tobacco and tobacco smoke. Prev Med 3: 277–293PubMedGoogle Scholar
  42. Schröter C, Parzefall W, Schröter H, Schulte-Hermann R (1987) Doseresponse study on effects of hexachlorocyclohexane on putative preneoplastic foci, monoxygenase and growth in liver. Cancer Res 47: 80–88PubMedGoogle Scholar
  43. Schulte-Hermann R (1985) Study on tumor promoters and apparent tumor stages in the liver. Arch Toxicol 57: 147–158CrossRefPubMedGoogle Scholar
  44. Scotto J, Fears TR, Fraumeni JF Jr (1983) Non-melanoma skin Cancer. US Department of Health and Human Services. NIH Publication No. 83–2433Google Scholar
  45. Southwick JW, Western AE, Beck MM, Whitley T, Isaacs, Petajan J, Hansen CD (1981) Community health associated with arsenic in drinking water in Millard County, Utah. US EPA Document 600/1-81-064Google Scholar
  46. Stöhrer G (1989) Arsenical disease in the United States. EPA 68-C8-0033-12Google Scholar
  47. Storz G, Tartaglia LA, Ames BN (1990) Transcriptional regulator of oxidative stress inducible genes: direct activation by oxidation. Science 248: 189–198PubMedGoogle Scholar
  48. Swenberg JA, Heck HA, Morgan KT, Starr MS (1987) A scientific approach to formaldehyde risk assessment. Banbury Report 25: 151–161Google Scholar
  49. Tseng W-P, Chu HM, How SW, Fong JM, Lin CS, Yeh S (1968) Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40: 453–463PubMedGoogle Scholar
  50. United States (1959) 21 USC 348(c) (3) (A)Google Scholar
  51. United States (1962) 1942 Drinking water standard. Referenced in: Drinking Water Standards Title 42, chapter 1, Part 72, Interstate Quarantine Federal Register 2152 (March 6, 1962)Google Scholar
  52. United States (1986) Safe Drinking Water Act Amendments. 42 USC 300 f et sequ.Google Scholar
  53. Upton AC (1988) In: Cothern CR, Mehlman MA, Marcus WL (eds) Risk assessment and risk management of industrial and environmental chemicals. Princeton Scientific Publishing Co, Inc, PrincetonGoogle Scholar
  54. US EPA (1976) Interim procedures and guidelines for health risk and economic impact assessments of suspected carcinogens. Federal Register 31: 21 402–21 405Google Scholar
  55. US EPA (1984) Health assessment document for inorganic arsenicGoogle Scholar
  56. US EPA (1986) Proposed guidelines for carcinogen risk assessmentGoogle Scholar
  57. US EPA (1987) Estimated national occurrence and exposure to arsenic in public drinking water suppliesGoogle Scholar
  58. US EPA (1988) Special report on ingested inorganic arsenicGoogle Scholar
  59. Welch WJ, Suhan JP (1986) Cellular and biochemical events in mammalian cells during and after recovery from physiological stress. J Cell Biol 103: 2035–2052CrossRefPubMedGoogle Scholar
  60. Wile U (1912) Arsenical keratosis and cancer. J Cutan Dis 10: 192–200Google Scholar
  61. Wolff GL, Roberts DW, Morissey DW, Greenman DL, Allen RR, Campbell WL, Bergman H, Nesnow S, Frith CH (1987) Tumorigenic response to lindane in mice: potentiation by a dominant mutation. Carcinogenesis 8: 1889–1897PubMedGoogle Scholar
  62. Yeh H (1973) Skin cancer in chronic arsenicism. Hum Pathol 4: 469–485PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Gerhard Stöhrer
    • 1
  1. 1.The Washington InstituteWashington, DCUSA

Personalised recommendations